1. Home
  2. EAF vs LCTX Comparison

EAF vs LCTX Comparison

Compare EAF & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GrafTech International Ltd.

EAF

GrafTech International Ltd.

HOLD

Current Price

$12.14

Market Cap

246.3M

Sector

Energy

ML Signal

HOLD

Logo Lineage Cell Therapeutics Inc.

LCTX

Lineage Cell Therapeutics Inc.

HOLD

Current Price

$1.04

Market Cap

251.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EAF
LCTX
Founded
1886
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
246.3M
251.4M
IPO Year
2018
1996

Fundamental Metrics

Financial Performance
Metric
EAF
LCTX
Price
$12.14
$1.04
Analyst Decision
Hold
Strong Buy
Analyst Count
4
7
Target Price
★ $9.00
$5.50
AVG Volume (30 Days)
582.1K
★ 1.4M
Earning Date
10-23-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $504,134,000.00
$14,556,000.00
Revenue This Year
$2.85
$4.38
Revenue Next Year
$20.35
$10.80
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 53.24
52 Week Low
$4.92
$0.88
52 Week High
$19.72
$2.09

Technical Indicators

Market Signals
Indicator
EAF
LCTX
Relative Strength Index (RSI) 70.56 56.46
Support Level $5.79 $1.02
Resistance Level $19.72 $1.05
Average True Range (ATR) 0.87 0.06
MACD 0.43 0.01
Stochastic Oscillator 99.05 96.66

Price Performance

Historical Comparison
EAF
LCTX

About EAF GrafTech International Ltd.

GrafTech International Ltd is a manufacturer of high-quality graphite electrode products essential to the production of EAF steel and other ferrous and non-ferrous metals. The company has only reportable segment, Industrial Materials, is comprised of its two product categories: graphite electrodes and petroleum needle coke products used as raw material in the production of graphite electrodes.

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.

Share on Social Networks: